Document Classification

Section Type: RESULTS

Text: (1) Percentages of CD19 (+) B-cells in active or peripheral joint involvement AS patients increased more obviously than those in stable or axial involvement alone AS patients (both P = 0. 001), and percentage of CD19 (+) CD27high B-cells in AS patients with peripheral joint involvement was significantly higher than that in cases with axial involvement alone or healthy volunteers (P = 0. 005 and 0. 006, respectively) ; (2) The percentage of CD19 (+) B-cells in AS patients was positively correlated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, Patient 's Global Assessment (PGA) scores, total back pain scores and nocturnal back pain scores (r = 0. 270, 0. 255, 0. 251 and 0. 266, P = 0. 029, 0. 039, 0. 042 and 0. 031, respectively) ; (3) At week 6 and week 12, there were no statistical differences of the percentages of B-cells and subsets between etanercept group and placebo group of AS patients (P > 0. 05) ; the percentage of CD19 (+) B-cells in etanercept group was higher than that in healthy volunteers at week 12 (t = 3. 320, P = 0. 003).